pubmed-article:8169417 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0032305 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0005149 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0068527 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0443199 | lld:lifeskim |
pubmed-article:8169417 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:8169417 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:8169417 | pubmed:dateCreated | 1994-6-2 | lld:pubmed |
pubmed-article:8169417 | pubmed:abstractText | Forty-three human immunodeficiency virus-infected patients with Pneumocystis carinii pneumonia (PCP) were enrolled in a study of adjunctive corticosteroid treatment for 10 days versus placebo, in addition to antimicrobial treatment. Levels of neopterin and beta 2-microglobulin (beta 2M) were determined in consecutive serum samples. Initiation of antimicrobial treatment resulted in significantly increased neopterin levels, whereas beta 2M levels slightly decreased from pretreatment levels. In patients treated with corticosteroid, both neopterin and beta 2M decreased, by approximately 50% and approximately 30%, respectively, and returned to baseline after discontinuation of corticosteroid treatment. Antimicrobial treatment alone did not affect either neopterin or beta 2M in healthy controls. Results indicate that treatment has a differential effect on the immune response: increased macrophage activation leading to neopterin production and decreased production of beta 2M by lymphocytes. Further, addition of corticosteroids modified and decreased this immune activation and may explain the earlier demonstrated beneficial effect of corticosteroids in PCP treatment. | lld:pubmed |
pubmed-article:8169417 | pubmed:language | eng | lld:pubmed |
pubmed-article:8169417 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:8169417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8169417 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8169417 | pubmed:month | May | lld:pubmed |
pubmed-article:8169417 | pubmed:issn | 0022-1899 | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:HofmannBB | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:JensenB NBN | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:LundgrenJ DJD | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:NielsenT LTL | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:SchattenkerkJ... | lld:pubmed |
pubmed-article:8169417 | pubmed:author | pubmed-author:BenfieldT LTL | lld:pubmed |
pubmed-article:8169417 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8169417 | pubmed:volume | 169 | lld:pubmed |
pubmed-article:8169417 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8169417 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8169417 | pubmed:pagination | 1170-3 | lld:pubmed |
pubmed-article:8169417 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:meshHeading | pubmed-meshheading:8169417-... | lld:pubmed |
pubmed-article:8169417 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:8169417 | pubmed:articleTitle | Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumonia. | lld:pubmed |
pubmed-article:8169417 | pubmed:affiliation | Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Netherlands. | lld:pubmed |
pubmed-article:8169417 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8169417 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:8169417 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:8169417 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8169417 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8169417 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8169417 | lld:pubmed |